White Paper: The Dalton Analytical Advantage
Published June 2026
Abstract
Analytical testing is the invisible infrastructure of pharmaceutical development. When it is planned well, integrated with manufacturing, and executed by a team with full programme context, it accelerates development timelines, strengthens regulatory submissions, and contributes actively to product quality at every stage.
This whitepaper highlights how Dalton’s analytical/microbiological services, built on scientific expertise, regulatory-ready systems, and strong cross-functional integration, are a strategic development asset, not simply a cost centre or a tick-box function. It covers the full scope of analytical requirements across the development lifecycle, the specific ways in which Dalton’s capabilities contribute to programme speed and quality, and what a fit-for-purpose analytical strategy looks like at each development and regulatory milestone.
This white paper aims to provide a broad overview of the following key topics in precision medicine:
- Analytical Testing: A Strategic Driver at Every Stage of Development
- The Full Scope of Analytical Requirements Across the Development Lifecycle
- The Dalton Analytical Difference: Expertise, Rigour, and Integration
Click here to view White paper: White Paper: The Dalton Analytical Advantage